Doxorubicin Hydrochloride, Liposomal — Drug Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

6 Recruiting

2 Completed trials

7 Sponsors

18 Countries

Phase III

Phase II/III

Phase II

Phase IV

Phase III: 5 Phase II/III: 1 Phase II: 1 Phase IV: 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Indications tested

Ovarian cancer 2 Fallopian tube cancer 2 Ovarian cancer recurrent 2 Hormone receptor positive breast cancer 2 Ovarian cancer metastatic 1 Breast cancer 1 Fallopian tube cancer metastatic 1 Ovarian epithelial cancer 1 Breast cancer metastatic 1 Hormone receptor positive HER2 negative breast cancer 1 Breast cancer female 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 3 AGO Research GmbH 1 AstraZeneca AB 1 Champalimaud Clinical Centre 1 Daiichi Sankyo Inc. 1 Rita Fior 1 Verastem Inc. 1

All trials

8 total

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Phase III 10 countries AstraZeneca AB
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting

2025-520582-51-00 Phase III 7 countries Merck Sharp & Dohme LLC
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Phase III 16 countries Merck Sharp & Dohme LLC
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting

2023-508204-38-00 Phase III 9 countries Verastem Inc.
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Phase II/III 9 countries Daiichi Sankyo Inc.
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 Phase II 1 country AGO Research GmbH
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Phase III 13 countries Merck Sharp & Dohme LLC

Showing 1–8 of 8 trials

← All drugs A–Z